KY19382 is discussed as a potential treatment for creating new hairfollicles and possibly curing hair loss. The conversation seeks user experiences and sourcing information for KY19382.
PP405 is a promising hair growth stimulant but not a cure for advanced hair loss, as it may only help dormant follicles. Treatments like Minoxidil, Finasteride, and Dutasteride are discussed, with emphasis on early intervention for effectiveness.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hairfollicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hairfollicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
Finasteride prevents further hair loss by blocking DHT, while minoxidil stimulates hair growth by prolonging the active phase of hairfollicles. Stopping minoxidil can lead to loss of regrown hair because finasteride does not address the same growth mechanism.
Finasteride stops hair loss by blocking DHT, while Minoxidil promotes hair growth by increasing blood flow to hairfollicles. Using both can help regrow hair, but results vary by individual.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hairfollicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
Nanoxidil may be more effective than Minoxidil for hair loss due to better follicle penetration, but it lacks widespread recognition and research because it's owned by a small company and classified as a cosmetic. The pharmaceutical system favors Minoxidil due to its established market presence and profitability, leaving Nanoxidil largely unstudied and unknown.
PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.
Scalp Botox may help hair loss by relaxing muscles and increasing blood flow, potentially benefiting conditions other than androgenetic alopecia. DHT affects hairfollicles differently, causing tension and hair loss in some areas but not others.
A deoxyribose sugar gel may work as well as minoxidil for hair regrowth by boosting blood supply to hairfollicles. Some users discuss combining it with minoxidil and cetrizine, but caution is advised due to potential risks and lack of consistent results.
SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hairfollicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.
The user experienced significant hair regrowth using finasteride and dutasteride, with noticeable results after switching to dutasteride. Minoxidil was deemed unnecessary due to the restoration of the hairline and lack of hairfollicles in bald spots.
The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hairfollicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.
The user experienced significant hair regrowth using topical Minoxidil and oral Finasteride over five months, with darker and thicker hair and new follicles appearing. They are considering waiting 1-2 years before deciding on a hair transplant, as further improvement is expected.
The user experienced hair regrowth and improved hair density using oral finasteride and topical minoxidil, with microneedling as an additional treatment. They are considering a hair transplant for low-density areas but are uncertain due to existing follicles.
User started Finasteride for hair loss and uses Toppik to cover bald spots. They wonder if Toppik's keratin fibers will block follicles and affect hair regrowth.
PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hairfollicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hairfollicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hairfollicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.
The user discusses using dutasteride to stop hair loss and bimatoprost for regrowth. They plan to use VEGF with hydrogels for potentially permanent hairfollicle improvement and suggest PRP as an alternative.
The "DHT itch" is real and likely due to inflammation at the hairfollicle, exacerbated by increased testosterone or androgens. Treatments mentioned include dutasteride, minoxidil, finasteride, and various topical solutions.
Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.
Microneedling with needle lengths of 1.5mm to 2.5mm to stimulate hairfollicle stem cells for potential hair growth. Using needles longer than 2.5mm is not recommended due to risk of puncturing veins in the scalp. A dermastamp is suggested over a roller.
How Finasteride and Dutasteride help reduce hair loss by reducing the amount of DHT in scalp areas, as well as discussing factors such as sensitivity to DHT, 5α-reductase expression in different parts of the hairfollicle, and scalp tension.
The conversation is about a hair loss treatment routine involving dermarolling, finasteride, minoxidil, and natural oils. Suggestions include using shorter needles for better absorption of treatments and longer needles less frequently for hairfollicle regeneration.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hairfollicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
An 18-year-old started taking finasteride for early-stage hair loss, prescribed by a dermatologist who advised against waiting due to potential follicle loss. The conversation includes differing opinions on starting finasteride early, with some users sharing personal experiences and concerns about potential side effects.